Articles from Truvian Health

Truvian Health (“Truvian”), a diagnostics company redefining routine blood testing, today announced U.S. Food and Drug Administration (FDA) clearance for the Complete Blood Count (CBC) on its TruVerus™ multi‑modal blood testing system (K251249).

Truvian Health (“Truvian”), a transformational diagnostics company redefining healthcare, today announced it has received 510(k) clearances (K251091, K251074, K251157) from the U.S. Food and Drug Administration (FDA) for nine additional analytes for TruVerus™, the industry’s first FDA cleared multimodal benchtop blood analyzer. The newly cleared tests expand the TruVerus menu into three new key categories: cardiovascular health, liver health, and core metabolic health.

Truvian Health (“Truvian”), a transformational diagnostics company redefining healthcare, today announced the appointment of Michael J. Mina, MD, PhD, as Chief Medical and Strategy Officer. Dr. Mina, a former Harvard professor and a globally recognized leader in epidemiology and diagnostic technology, joins Truvian as the company accelerates its mission to decentralize blood testing following the recent FDA clearance of its TruVerus™, a multimodal blood analyzer.

Truvian Health (“Truvian”) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance (K251058) for TruVerus™, the industry’s first multimodal blood testing benchtop instrument. This clearance represents a major milestone in Truvian’s mission to deliver a full menu of routine blood testing results wherever care happens.

Truvian Health (“Truvian”) today announced the appointment of David P. King to its Advisory Board. King brings decades of diagnostics and business experience with a distinguished track record of advancing innovation and shaping corporate strategy.

Truvian Health (“Truvian”) today announced the appointment of Tina S. Nova, Ph.D., to its Board of Directors. Dr. Nova has more than two decades of experience serving as an executive and board member in some of the most storied franchises in diagnostics and biotech.

Access to healthcare is a fundamental human right. Yet to this day, routine blood testing is limited across the globe. Truvian Health (“Truvian”) is redefining the current global infrastructure through its novel platform, creating a world where central laboratory equivalent blood tests are available anywhere you go. Today, Truvian is announcing an injection of $74 million of capital to be used in part to secure US Food and Drug Administration (FDA) clearance for its blood testing platform.

Truvian Health, a transformational and data-driven diagnostics company, today presented results from a recent multi-site clinical study at the 2023 American Association for Clinical Chemistry Annual Scientific Meeting demonstrating the ability of its benchtop blood testing platform to deliver central laboratory quality results simultaneously across a large panel of assays.

Truvian Health, a transformational and data-driven diagnostics company, announced that next month, the company will present findings from initial clinical validation studies of its blood testing solution at the 2023 American Association of Clinical Chemistry (AACC) Annual Scientific Meeting in Anaheim, Calif. Truvian initiated a multisite clinical study earlier this year to evaluate the performance of its platform against industry leading machines used in central lab settings when processing more than 30 of the most commonly ordered blood tests, which are frequently used to illuminate health insights to prevent disease and for chronic disease monitoring and maintenance.